このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

標準的なアジュバント療法の有無にかかわらず、切除後の非小細胞肺癌の参加者に対するペムブロリズマブ(MK-3475)とプラセボの比較(MK-3475-091 / KEYNOTE-091) (PEARLS)

2026年10月28日 更新者:Merck Sharp & Dohme LLC

切除および標準補助療法(PEARLS)の完了後の早期NSCLC患者に対する抗PD-1モノクローナル抗体ペムブロリズマブ(MK-3475)対プラセボによる無作為化第3相試験

In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

1177

段階

  • フェーズ 3

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Pathological diagnosis of NSCLC confirmed at surgery, any histology. Participants with two synchronous primary non-small cell lung cancers are excluded from the study
  • Union for International Cancer Control (UICC) v7 Stage IB with T ≥ 4 cm, II-IIIA NSCLC after complete surgical resection with resection margins proved microscopically free of disease (R0). Carcinoma in situ can be present at the bronchial margin
  • Available tumor sample obtained at surgical resection for programmed cell death ligand-1 (PD-L1) Immunohistochemistry (IHC) expression assessment
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • Adequate organ function performed within 10 days of treatment initiation
  • Female participants of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first infusion of study medication). If the urine test cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the participant to be eligible
  • Female participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity starting with the first infusion of study treatment through 120 days after the last infusion of study treatment
  • Female participants who are breast feeding must discontinue nursing prior to the first infusion of study medication and until 120 days after the last infusion study treatment
  • Male participants must agree to use an adequate method of contraception starting with the first infusion of study treatment through 120 days after the last infusion of study treatment
  • Absence of severe comorbidities that in the opinion of the Investigator might hamper the participation to the study and/or the treatment administration
  • No prior or planned neo-adjuvant or adjuvant radiotherapy and/or neo-adjuvant chemotherapy for the current malignancy is allowed

Exclusion Criteria:

  • Evidence of disease at clinical examination and/or baseline radiological assessment as documented by contrast enhanced chest/upper abdomen CT scan, brain CT/MRI and clinical examination
  • More than 4 cycles of adjuvant therapy
  • Prior treatment with anti-programmed cell death (anti-PD)-1, anti-PD ligand-1/2, anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulators or any other immune-modulating agents
  • Live vaccine within 30 days prior to the first infusion of study treatment
  • Current participation or treatment with an investigational agent or use of an investigational device within 4 weeks of the first infusion of study treatment
  • History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive). No known active Hepatitis B or C
  • Chronic use of immunosuppressive agents and/or systemic corticosteroids or any use in the last 3 days prior to the first infusion of study treatment
  • History of interstitial lung disease or (non-infectious) pneumonitis that required oral or IV steroids (other than COPD exacerbation) or current pneumonitis
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • History of a hematologic or primary solid tumor malignancy, unless in remission for at least 5 years with the exception of pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanomatous skin cancer or carcinoma in situ of the cervix
  • Previous allogeneic tissue/solid organ transplant
  • Active infection requiring therapy
  • Surgery- or chemotherapy-related toxicity (non-hematological) not resolved to Grade 1 with the exception of alopecia, fatigue, neuropathy and lack of appetite /nausea
  • Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last infusion of study treatment
  • Participant will not be eligible if the participant is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective site Review Board approval is given allowing exception to this criterion for a specific participant

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Pembrolizumab

Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).

IV infusion

他の名前:
  • MK-3475
  • キイトルーダ®
プラセボコンパレーター:Placebo

Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).

IV infusion

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Disease-Free Survival (DFS)
時間枠:Up to approximately 84 months

DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.

Up to approximately 84 months
DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%
時間枠:Up to approximately 84 months

DFS in PDL-1 strong positive participants with TPS ≥50% was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.

Up to approximately 84 months

二次結果の測定

結果測定
メジャーの説明
時間枠
DFS in PDL-1 Positive Participants With TPS ≥1%
時間枠:Up to approximately 84 months

DFS in PDL-1 positive participants with TPS ≥1% was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.

Up to approximately 84 months
Overall Survival (OS)
時間枠:Up to approximately 120 months

OS was defined as the time from randomization to the date of death.

Up to approximately 120 months
OS in PDL-1 Strong Positive Participants With TPS ≥50%
時間枠:Up to approximately 120 months

OS in PDL-1 strong positive participants with TPS ≥50% was defined as the time from randomization to the date of death.

Up to approximately 120 months
OS in PDL-1 Positive Participants With TPS ≥1%
時間枠:Up to approximately 120 months

OS in PDL-1 positive participants with TPS ≥1% was defined as the time from randomization to the date of death.

Up to approximately 120 months
Lung Cancer Specific Survival (LCSS)
時間枠:Up to approximately 120 months

LCSS was defined as the time from randomization to the date of death (due to lung cancer specifically).

Up to approximately 120 months
Number of Participants Who Experienced an Adverse Event (AE)
時間枠:Up to approximately 22 months

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who experienced an AE were reported.

Up to approximately 22 months
Number of Participants Who Discontinued Study Treatment Due to an AE
時間枠:Up to approximately 19 months

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. The number of participants who discontinued study treatment due to an AE were reported.

Up to approximately 19 months

その他の成果指標

結果測定
メジャーの説明
時間枠
DFS at 68 Months
時間枠:Up to approximately 68 months

DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.

Up to approximately 68 months
DFS at 68 Months in Participants Who Received Adjuvant Chemotherapy
時間枠:Up to approximately 68 months

DFS was defined as the time from randomization to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.

Up to approximately 68 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • スタディディレクター:Medical Director、Merck Sharp & Dohme LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年11月6日

一次修了 (実際)

2023年1月24日

研究の完了 (実際)

2026年1月21日

試験登録日

最初に提出

2015年7月20日

QC基準を満たした最初の提出物

2015年7月20日

最初の投稿 (推定)

2015年7月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年10月28日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 3475-091
  • 2015-000575-27 (EudraCT番号)
  • EORTC-1416-LCG (その他の識別子:EORTC)
  • 163457 (レジストリ識別子:JAPIC-CTI)
  • MK-3475-091 (その他の識別子:MSD)
  • KEYNOTE-091 (その他の識別子:MSD)
  • 2023-509137-39-00 (レジストリ識別子:EU CT)
  • U1111-1309-6051 (レジストリ識別子:UTN)
  • 2023 (米国 NIH グラント/契約)
  • 2015 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。